BMS earns ENERGY STAR Partner of the Year Award for third consecutive year
Company has achieved an annual energy intensity improvement of more than 3% globally, contributing to an 11.4% reduction in energy consumption since 2010.
For the third consecutive year, the US Environmental Protection Agency (EPA) recognizes Bristol-Myers Squibb (BMS) with an ENERGY STAR Partner of the Year Award for outstanding efforts to improve the energy efficiency of facilities worldwide. The award reaffirms BMS’s commitment being a good global citizen through driving sustainable and impactful improvements in energy performance across all of its sites worldwide, resulting in energy reductions, avoided costs and lowered emissions.
"We are very pleased that our environmental efforts have been recognized for the third year through the ENERGY STAR Partner program", said Carol Ryerkerk Powell, global head and vice president of Environment, Health, Safety and Sustainability, BMS. "This recognition is a testament to our employees who work every day across our company to promote environmental sustainability. Our corporate energy program, with the support of Energy Star tools and resources, has made a significant positive impact to the environment, to our communities and to our employees. BMS forward to furthering our commitment with Energy Star as we strive to continuously improve our corporate energy management program."
The Energy Management designation is awarded to organizations for adopting a continuous energy management strategy across the organization's entire portfolio of buildings and plants.
BMS was recognized for the following accomplishments, among others:
In addition to the company’s recognition as an ENERGY STAR Partner of the Year, the BMS research and development site in Hopewell, New Jersey, earned the 2017 Challenge for Industry recognition. The ENERGY STAR Challenge for Industry is a national call-to-action to improve energy efficiency of America’s manufacturers by 10% or more. By taking the ENERGY STAR Challenge, sites set a goal to reduce their energy intensity by 10% within 5 years. To earn this recognition, the Hopewell site upgraded and optimized its chilled water plants, retrofitted two main boilers and the HVAC systems and performed full LED lighting upgrades, among other improvements.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.